Home > Result Summaries: Compounds > paroxetine Result Summaries: paroxetine GSKStudy ID Phase Title Summary (Download) 100690 phase 1 A randomised, double blind triple dummy, placebo controlled balanced incomplete block crossover study to evaluate the change in response to a 7% CO2 challenge and pharmacokinetics of single oral doses of a new chemical entity (NCE) and paroxetine (5 or 7.5 mg) either alone or in combination, or ... (0 citation(s)) 104228 phase 4 Post-marketing clinical study on PAXIL Tablet in patients with depression or depressive mood - A study on combination of PAXIL Tablet and benzodiazepines (0 citation(s)) 111951 n\a First trimester Paroxetine use and the occurrence of congenital malformations: Systematic review and meta-analysis of epidemiological data (0 citation(s)) 112301 phase 4 Drug Use Investigation for PAXIL Tablet (0 citation(s)) 112302 phase 4 Special Drug Use Investigation for PAXIL Tablet (Long-term) (0 citation(s)) 112304 phase 4 Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression) (2 citation(s)) 112307 phase 4 Special Drug Use Investigation for PAXIL TABLET (Long-term:obsessive-compulsive disorder) (0 citation(s)) 112308 phase 4 Special Drug Use Investigation for PAXIL Tablet (Investigation in case of administered from 20mg/day) (0 citation(s)) 112309 phase 4 Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder) (0 citation(s)) 112390 Phase 4 A Post-Marketing Clinical Study of Paroxetine Hydrochloride Hydrate in Patients with Depression or Depressive Episode -A Double-Blind, Imipramine Hydrochloride-Controlled, Comparative Study - (0 citation(s)) 112487 phase 4 A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder<Post-marketing clinical study> (0 citation(s)) 112810 phase 3 A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder (1 citation(s)) 112811 phase 1 An open label, randomized, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single doses of the controlled-release paroxetine tablets at the dose levels of 12.5, 25 and 50mg in healthy Japanese male subjects (0 citation(s)) 112812 phase 1 A steady-state, two-period crossover study to compare the pharmacokinetic profile of paroxetine after repeated daily dosing of the controlled-release paroxetine tablet (25 mg) with that of the standard immediate-release paroxetine tablet (20 mg) in healthy Japanese male subjects (0 citation(s)) 113655 N/ Paroxetine (Paxil®) in relation to birth defects (Slone) (1 citation(s)) 113670 N/ Paroxetine use and the risk of suicidal behavior: Selective prescribing and outcomes following treatment (2 citation(s)) 113694_1 N/A EPIDEMIOLOGY STUDY: Preliminary Report on Bupropion in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation (1 citation(s)) 113694_2 N/A EPIDEMIOLOGY STUDY: Updated Preliminary Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation (1 citation(s)) 113694_4 N/A EPIDEMIOLOGY STUDY: Final Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformations (1 citation(s)) 113939 phase 1 Relative bioavailability study between the formulations: Paroxetine 25 mg tablet with controlled release manufactured by GSK Mississauga and Paroxetine 25 mg tablets with controlled release manufactured by SmithKline Beecham (Cidra), fasted administration in healthy volunteers for both genders. (0 citation(s)) 114035 phase 1 Relative bioavailability study between the formulations: Paroxetine 25 mg tablets with controlled release manufactured by GSK Mississauga and Paroxetine 25 mg tablets with controlled release manufactured by SmithKline Beecham (Cidra), fed administration in healthy volunteers of both genders (0 citation(s)) 114398 n\a Paroxetine Pharmacokinetics Gender Differences (0 citation(s)) 116554 n\a Incident Type II Diabetes Mellitus Among Patients Exposed to the Combination of Pravastatin and Paroxetine (0 citation(s)) 1991_Dataset N/A Analysis of suicide attempts in paroxetine clinical trials for the adult clinical trial population (0 citation(s)) 2001_Dataset N/A Results of the investigation of suicide attempts and suicidal thinking identified by ‘narrow’ and ‘broad’ definition algorithms in the adult clinical trial population (2001 Dataset). (0 citation(s)) 2003-Pediatric-Review N/A Paediatric-only clinical trials results of investigation of suicide attempts and “possibly suicide-related” events (2003 Paediatric Review). (0 citation(s)) 26090/007 Phase 3 A Double-Blind Placebo Controlled Study to Compare Paroxetine with Maprotiline in the Treatment of Depression (0 citation(s)) 29060/001/081 Phase 3 An Open Pharmacokinetic and Pharmacodynamic Study of Paroxetine (20mg, 30mg, or 40mg daily) in the Treatment of Major Depressive Disorder (DSM III) (0 citation(s)) 29060/004 Phase 3 A Double-Blind Extension of Protocol PAR 03 (2 citation(s)) 29060/005 Phase 2 A Open-label Long-term Evaluation of Paroxetine in Depressed Outpatients (2 citation(s)) 29060/005_3 Phase 3 An Investigation of the Pharmacokinetics of Paroxetine in Geriatric Patients with Depression (0 citation(s)) 29060/006 Phase 3 A study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo (1 citation(s)) 29060/008 Phase 1 An Open-label, Single-dose, Five-period Crossover Evaluation of the Pharmacokinetic Properties of Paroxetine When Administered by Oral Route (0 citation(s)) 29060/009 Phase 2 A Multicenter, Double-blind, Placebo-controlled Fixed-dose Evaluation of Four Doses of Paroxetine (1 citation(s)) 29060/01/001 Phase 2 A Phase II, Placebo-Controlled, Double-Blind Study of Paroxetine in Depressed Outpatients (0 citation(s)) 29060/010 Phase 1 A multiple-dose, steady-state design pharmacokinetic evaluation of the interaction between paroxetine and diazepam (1 citation(s)) 29060/011 Phase 2 Two Combined Multi-Center, Doxepin-Controlled, Double-Blind Studies of Paroxetine in Geriatric Outpatients with Major Depressive Disorder (1 citation(s)) 29060/012 Phase 1 A Placebo-controlled, single-dose, five-period crossover evaluation of the pharmacokinetic properties of paroxetine when administered by the oral route (0 citation(s)) 29060/012/280 Phase 3 An Investigation of the Efficacy and Tolerance of Paroxetine in an Open Study of Patients with Depression and Obsessive Compulsive Disorder (0 citation(s)) 29060/012_3 Phase 3 A Study to Assess the Effectiveness and Tolerance of Paroxetine by Double-Blind Comparison with Placebo and Mianserin (0 citation(s)) 29060/013 Phase 1 A multiple-dose, steady-state design, pharmacokinetic evaluation of the interaction between paroxetine and cimetidine (0 citation(s)) 29060/014 Phase 1 A multiple-dose, steady-state design, pharmacokinetic evaluation of the interaction between paroxetine and warfarin (0 citation(s)) 29060/015 Phase 1 A multiple-dose, steady-state design, pharmacokinetic evaluation of the interaction between paroxetine and digoxin (1 citation(s)) 29060/016 Phase 1 A multiple dose, steady-state, cross-over, replicate-sample evaluation of the bioequivalence of a tablet and capsule formulation of paroxetine. (0 citation(s)) 29060/02/001 Phase 2 A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients (5 citation(s)) 29060/02/002 Phase 2 A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients (4 citation(s)) 29060/02/003 Phase 2 A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients (4 citation(s)) 29060/02/004 Phase 2 A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients (3 citation(s)) 29060/020 Phase 3 An Interim Report of a Study to Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double-Blind Comparison with Mianserin (0 citation(s)) 29060/022 Phase 3 A Study To Assess the Efficacy and Tolerance of Paroxetine In Patients with Depression by Double-Blind Comparison with Mianserin (0 citation(s)) 29060/024 Phase 3 Safety and Efficacy Aspects of a Study to Investigate the Pharmacokinetics of Paroxetine in Younger Depressed Patients.A Study to Investigate the Pharmacokinetics of Paroxetine in Younger Depressed Patients. (0 citation(s)) 29060/025 Phase 3 Double Blind Parallel Group Study Comparing Paroxetine 30mg daily, and Clomipramine 100mg daily, in Depressed In-Patients. (0 citation(s)) 29060/026 Phase 3 An Interim Report to Evaluate the Efficacy and Tolerability of Paroxetine in the Treatment of Elderly Depressed Patients. A Double-blind Parallel Group Comparison with Mianserin. (1 citation(s)) 29060/027 Phase 3 A Study to Assess the Effectiveness and Tolerance of Paroxetine in the Treatment of Depression by Double-Blind Comparison with Imipramine (1 citation(s)) 29060/028 Phase 3 An Interim Report of a Study to Assess the Efficacy and Tolerability of Paroxetine in the Elderly, by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic (0 citation(s)) 29060/028/184 Phase 3 An Interim Report to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic (0 citation(s)) 29060/029 Phase 3 An Assessment of the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic. (1 citation(s)) 29060/03/001 Phase 3 A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients (3 citation(s)) 29060/03/002 Phase 3 A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients (4 citation(s)) 29060/03/003 Phase 3 A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients (2 citation(s)) 29060/03/004 Phase 3 A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients (3 citation(s)) 29060/03/005 Phase 3 A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients (3 citation(s)) 29060/03/006 Phase 3 A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients (3 citation(s)) 29060/03/019 Phase 3 Assessment of the efficacy and tolerability of paroxetine by double blind comparison with amitriptyline in depressed patients (1 citation(s)) 29060/030 Phase 3 An Assessment of the Efficacy and Tolerability of Paroxetine by Double Blind Comparison with Mianserin in Patients Referred to a Psychiatric Clinic (0 citation(s)) 29060/032 Phase 3 A Double Blind Study to Compare the Efficacy and Tolerability of Paroxetine and Amitriptyline in a Multi-Centre General Practice Study in Depressed Patients (0 citation(s)) 29060/033 Phase 1 An Examination of Paroxetine and Other Antidepressants Alone and in Combination with Alcohol, on Car Driving and Psychomotor performance. (1 citation(s)) 29060/034 Phase 3 A Study to Assess the Efficacy and Tolerability of Paroxetine in Epileptic Patients with Depression (0 citation(s)) 29060/035 Phase 3 A Double-Blind Study to Assess the Efficacy and Tolerance of Paroxetine in Comparison with Amitriptyline in the Treatment of Depression (0 citation(s)) 29060/037 Phase 3 The Short Term Phase of an Open, Long-Term, Safety and Tolerability Study of Paroxetine in Patients Suffering from Depression (0 citation(s)) 29060/038 Phase 3 To Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double Blind Comparison with Mianserin (0 citation(s)) 29060/040 Phase 2 Clinical aspects of a study to investigate the pharmacokinetics of paroxetine in elderly depressed patients (0 citation(s)) 29060/041 Phase 3 A Study to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison of Morning and Evening Dosages (1 citation(s)) 29060/042 Phase 3 A Study to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison of Morning and Evening Doses in the Elderly. (0 citation(s)) 29060/043 Phase 3 An Interim Report of a Study to Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double-Blind Comparison with Amitriptyline (A follow-up final report was not prepared and is not expected for this study). (1 citation(s)) 29060/044 Phase 3 A Double-blind Comparative Two-centre Study to Assess the Efficacy and Tolerability of Paroxetine (20mg vs 30mg) in Elderly Depressed Patients (1 citation(s)) 29060/046 Phase 3 A Study to Assess the Efficacy and Tolerance of Paroxetine in Elderly Depressed Patients by Double-Blind Comparison with Amitriptyline (1 citation(s)) 29060/048 Phase 1 A study to assess the interaction of paroxetine with digoxin in normal healthy volunteers (0 citation(s)) 29060/049 Phase 3 A Multi-Centre General Practice Study to Compare the Effectiveness and Tolerability of Paroxetine in Elderly Depressed Patients by Double Blind Comparison with Amitriptyline (2 citation(s)) 29060/051 Phase 1 A study to compare the bioequivalence of two formulations of paroxetine, a 30 mg tablet and 3 x10 mg capsules (0 citation(s)) 29060/052 Phase 1 A study to compare the bioequivalence of two formulations of paroxetine: a 30 mg film-coated tablet and a 30 mg caplet (0 citation(s)) 29060/053 Phase 1 A Double-Blind, Placebo Controlled, Comparative Investigation of the Effects on Psychomotor Performance of Paroxetine and Amitriptyline with or without alcohol in Adult Subjects. (1 citation(s)) 29060/056 Phase 3 A double-blind, between patient, multicentre study in general practice comparing the efficacy and tolerability of paroxetine with those of dothiepin in the treatment of elderly depressed patients (0 citation(s)) 29060/057 Phase 3 A Double-blind comparative multicentre study of paroxetine plus supportive psychotherapy and psychotherapy alone in the prevention of recurrent suicidal behavior and episodes of intermittent brief depression (0 citation(s)) 29060/058 Phase 1 A double-blind, placebo controlled, randomised, single dose, cross-over study comparing the effects on objective and subjective sleep, and awakening and early morning behaviour, of paroxetine 20 mg, 30 mg and 40 mg morning dose, 30 mg evening dose, and fluoxetine 40 mg morning dose in healthy vo ... (1 citation(s)) 29060/061 Phase 3 A Double-blind Comparative Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Geriatric Patients with Major Depression (1 citation(s)) 29060/062 Phase 1 An Interaction Study of Paroxetine on Lithium Plasma Levels in Depressed Patients Stabilised on Lithium Therapy (1 citation(s)) 29060/063 Phase 4 A double blind randomised trial comparing the effects on sleep of paroxetine 30mg daily and amitriptyline 150mg daily in patients with major depression. (0 citation(s)) 29060/064 Phase 3 A Double-blind Comparative Multicentre Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Depressed Patients (1 citation(s)) 29060/065 Phase 3 A Double-blind Comparative Study Comparing Paroxetine 20mg-40mg/day with Maprotiline 50mg-150mg/day in Major Depression: Clinical and Biochemical Aspects (1 citation(s)) 29060/067 Phase 3 A combined Report on the Clinical Aspects of Three Pharmacokinetic Studies of Paroxetine in the Treatment of Major Depressive Disorder (DSM III) (0 citation(s)) 29060/069 Phase 3 A Multicentre, Parallel Group Study to Compare the Efficacy and Tolerability of Paroxetine with Clomipramine in Elderly Patients. (1 citation(s)) 29060/07/001 Phase 2 A Double-Blind Comparison of Paroxetine, Amitriptyline, and Placebo in Inpatients with Major Depressive Disorder with Melancholia (0 citation(s)) 29060/070 Phase 3 A multicentre, double-blind, parallel group, randomised dose study comparing the efficacy of paroxetine 20mg increasing to 30mg daily if there is insufficient response and clomipramine 60mg increasing to 75mg daily, in outpatients (age &gt;60 years) with moderate depression according to… (1 citation(s)) 29060/073 Phase 3 A Multicentre, Double-blind Randomised Dose Titration Study Comparing the Efficacy and Safety Profiles of an Increasing Dose Regimen of Oral Paroxetine and Oral Amitriptyline in Adult Patients with Major Depression (1 citation(s)) 29060/075 Phase 1 A Sub-Chronic Comparison of the Effects of Paroxetine Versus those of Amitriptyline and Placebo on Fundamental Perceptual-Motor Skills and Actual Driving Performance (1 citation(s)) 29060/076 Phase 3 The Effects of Paroxetine Versus Those of Maprotiline and Placebo on Fundamental Cognitive Functions, Perceptual-Motor Skills and Eye Movements in Depressed Patients (0 citation(s)) 29060/078 Phase 3 A Multicentre Double Blind Study Comparing Paroxetine at a Dose of 20mq Increasing to 30mg Taken in the Morning and Amitriptyline 75mg Increasing to 150mg in Divided Doses in Adult Patients with Major Depressive Disorder (1 citation(s)) 29060/079 Phase 3 A double-blind comparative multicentre study comparing paroxetine b.d. (twice daily) with fluoxetine (Prozac®) b.d. (twice daily) in depressed patients (1 citation(s)) 29060/082 Phase 3 A Double-blind Comparative Multicentre Study Comparing Paroxetine 20-40mg/day with Maprotiline 50-150mg/day in Major Depression (1 citation(s)) 29060/083 Phase 3 A Double-blind Comparative Multicentre Study of Paroxetine and Placebo in Preventing Depressive Episodes in Recurrent Major Depressive Disorders (1 citation(s)) 29060/084 Phase 3 A Double Blind Comparative Study of the Effects of Paroxetine and Clomipramine on Cognitive Function in Elderly Patients with Major Depression (0 citation(s)) 29060/086 Phase 4 A Controlled Double-blind Randomised Parallel Group Study Comparing the Effects of Paroxetine and Maprotiline in the Treatment of Out-Patients with Major and Minor Depression (2 citation(s)) 29060/087 Phase 3 A double-blind, randomised, multicentre study comparing paroxetine 20mg daily versus fluoxetine 20mg daily in the treatment of adults with major depression with regard to antidepressant efficacy, tolerance and anxiolytic effect. (2 citation(s)) 29060/088 Phase 3 A Report on a Randomised, Double-Blind Comparative Study Including Evaluation of Effect Profiles and Correlations Between Plasma Concentration and Effect. (1 citation(s)) 29060/089 Phase 3 A Double-Blind Study to Compare the Efficacy and Tolerability of Paroxetine with Imipramine in Depressed Patients: An Interim Report (A final report has not been prepared and is not expected for this study). (1 citation(s)) 29060/090 Phase 3 Paroxetine and Imipramine in the Treatment of Depressive States in Psychiatric Specialist Practice - a Double-Blind Controlled Group Comparison (2 citation(s)) 29060/091 Phase 1 A study to investigate the effects of co-administration of three anticonvulsants (carbamazepine, valproate and phenytoin) and paroxetine in epileptic patients. (0 citation(s)) 29060/092 Phase 3 A double-blind, between patient, multicentre study comparing the efficacy, tolerability and effects on cognitive function of paroxetine with those of lofepramine in depressed patients in general practice (1 citation(s)) 29060/094 Phase 3 A Double-Blind Study to Assess The Safety And Tolerability of Paroxetine 60mg And To Compare Two Dosing Regimens (0 citation(s)) 29060/095 Phase 3 A double-blind comparative study of withdrawal effects following abrupt discontinuation of treatment with paroxetine in low or high dose or imipramine (0 citation(s)) 29060/097 Phase 4 ECT and paroxetine/imipramine combination treatment in depressive states. A clinical study of the safety of co-administration of ECT and paroxetine or imipramine, and relapse prevention in the maintenance phase. (4 citation(s)) 29060/103 Phase 3 A Double-Blind, Multicentre Study Comparing the Efficacy, Tolerability and Effects on Cognitive Functionof Paroxetine With Those of Lofepramine in Elderly Depressed Hospital In- or Out-Patients (0 citation(s)) 29060/105 Phase 1 An open study to investigate the effects of paroxetine (30 mg OD for 14 days) on sparteine oxidasepolymorphism in healthy volunteer subjects. (1 citation(s)) 29060/106 Phase 3 A double-blind comparative study of paroxetine and placebo in the treatment of episodes of intermittent brief depression (IBD) (0 citation(s)) 29060/108 Phase 3 Paroxetine in Panic Disorder. A double-blind, randomised, multi-centre, placebo-controlled study of paroxetine in combination with psychotherapy in the treatment of patients with panic disorder (DSM-III-R). (1 citation(s)) 29060/109 Phase 3 A double-blind, short-term comparison of paroxetine and amitriptyline with a 12-month, rater-blind maintenance phase comparing paroxetine, amitriptyline and lithium in the prevention of depressive relapse in patients with major depression, recurrent. (1 citation(s)) 29060/110 Phase 1 A double-blind, placebo-controlled study to assess the effects of paroxetine on the bleeding time of healthy volunteers (0 citation(s)) 29060/112 Phase 3 A double-blind, multicentre study to compare the effectiveness and tolerance of paroxetine versus fluvoxamine in depressed patients (1 citation(s)) 29060/113 Phase 1 An open study to investigate the effects of repeated dosing of paroxetine (20 mg od for 20 days) on the pharmacokinetics and metabolism of a single dose of desipramine (100 mg) in healthy volunteer subjects. (1 citation(s)) 29060/115 Phase 3 A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder. (0 citation(s)) 29060/116 Phase 3 Paroxetine versus Placebo in the Treatment of Obsessive-Compulsive Disorder (2 citation(s)) 29060/118 Phase 3 Paroxetine versus Clomipramine and Placebo in the Treatment of Obsessive-Compulsive Disorder (0 citation(s)) 29060/120 Phase 3 A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40 mg) given as a single oral dose daily, in the treatment of panic disorder. (2 citation(s)) 29060/121 Phase 1 A repeat-dose steady-state crossover evaluation of the bioequivalence of a tablet formulation (20 mg marketing formulation, CIDRA) and a capsule formulation (10 mg CT capsule P47) of paroxetine (0 citation(s)) 29060/121/126/262 Phase 3 The Short Term Phase of an Open, Long Term Study of Paroxetine in Elderly Patients Suffering from Depression (1 citation(s)) 29060/122 Phase 2 An Interim Report on the Short-term Phase of a Long-term Phase II Open Study to Evaluate Tolerance and Safety of Paroxetine Treatment of Depressive States (a final report was not issued). (0 citation(s)) 29060/125 Phase 1 A double-blind, placebo-controlled study to assess the effects of paroxetine on the bleeding time and prothrombin time of volunteers receiving warfarin therapy (0 citation(s)) 29060/126 Phase 3 Long-term Treatment with Paroxetine of Outpatients with Obsessive-Compulsive Disorder. An Extension of the Fixed-Dose Study (Study 116). (3 citation(s)) 29060/127 Phase 3 Long-term treatment with paroxetine of outpatients with obsessive-compulsive disorder: An extension of the companion study. (0 citation(s)) 29060/128 Phase 3 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of Paroxetine and Fluoxetine in the Treatment of Major Depressive Disorder (0 citation(s)) 29060/131 Phase 3 A Double-Blind, Randomized, Multicentre Comparison of Paroxetine and Fluoxetine in the Treatment of Patients With Major Depression With Regard to Antidepressant Efficacy, Tolerance and Anxiolytic Effect (2 citation(s)) 29060/134 Phase 3 A randomized, double-blind, controlled study of paroxetine and fluoxetine in the treatment of patients with major depression with associated anxiety. Extensive searching has revealed that no clinical study report is available for this study. (1 citation(s)) 29060/135 Phase 4 A Comparative Double-Blind Study of Paroxetine and Fluoxetine in the Treatment of Depression in Out-Patients (1 citation(s)) 29060/136 Phase 3 A Double-Blind Study to Assess the Efficacy and Tolerance of a Flexible Dose of Paroxetine Compared with a Flexible Dose of Clomipramine and Placebo in the Treatment of Obsessive Compulsive Disorder. (1 citation(s)) 29060/139 Phase 1 A study of the pharmacokinetics of paroxetine after single oral doses of BRL 29060A (0 citation(s)) 29060/140 Phase 1 Double-blind tolerance study of 30 mg of paroxetine (0 citation(s)) 29060/141 Phase 1 A comparison of the pharmacokinetics of paroxetine after a single oral dose before and after 30 days of once daily oral administration (0 citation(s)) 29060/142 Phase 1 A study to assess the CNS effects of paroxetine and any interaction with the sedative effects of amylobarbitone (2 citation(s)) 29060/143 Phase 1 A study to assess the effect of repeat dosing with paroxetine 30 mg once daily on the pharmacokinetics of phenytoin in healthy male volunteers (0 citation(s)) 29060/144 Phase 1 Pharmacokinetic profile of antipyrine before and after the administration of paroxetine (1 citation(s)) 29060/145 Phase 1 Metabolism studies in healthy male subjects following a single oral dose of 14C-BRL 29060A equivalent to 30mg pure free base (0 citation(s)) 29060/146 Phase 1 A comparative study of the pharmacokinetics of paroxetine in females who were and were not taking oral contraceptives (0 citation(s)) 29060/147 Phase 1 A study of the effects of a single oral dose of paroxetine on systolic time intervals, compared with amitriptyline and placebo (0 citation(s)) 29060/148 Phase 1 A study to determine the tolerance, clinical effects and bioavailability of paroxetine in healthy male human volunteers (0 citation(s)) 29060/150 Phase 1 A study of the tolerance, pharmacokinetics and absolute bioavailability of BRL 29060A. (0 citation(s)) 29060/151 Phase 1 A study to assess the CNS effects of paroxetine (BRL 29060A) and amitriptyline and their interaction with alcohol (0 citation(s)) 29060/152 Phase 1 Two-part sequential study of the pharmacokinetic profile of 30 mg tablets of paroxetine after morning and evening administration (0 citation(s)) 29060/153 Phase 1 An investigation into the pharmacokinetics of BRL 29060 (paroxetine) in patients with impaired renal function (1 citation(s)) 29060/154 Phase 1 Two-part sequential study comparing absorption of 30 mg tablets of paroxetine in fasting and non-fasting volunteers (0 citation(s)) 29060/155 Phase 1 A study to assess the CNS effects of oxazepam alone and in combination with paroxetine (1 citation(s)) 29060/156 Phase 1 A study to assess the CNS effects of paroxetine, and haloperidol and any interaction of paroxetine with the sedative effects of haloperidol (1 citation(s)) 29060/157 Phase 1 Bioequivalence of four formulations of paroxetine (0 citation(s)) 29060/158 Phase 1 A placebo controlled, double-blind, 28 day repeat dose tolerance study on paroxetine (0 citation(s)) 29060/159 Phase 1 Double-blind tolerance study of 40 mg of paroxetine. (0 citation(s)) 29060/160 Phase 1 Bioavailability of two formulations of paroxetine (0 citation(s)) 29060/161 Phase 1 An investigation into the action of oral paroxetine on upper gastro-intestinal activity in man using the lactulose/breath hydrogen method (0 citation(s)) 29060/162 Phase 1 An investigation into the action of oral paroxetine on upper gastro-intestinal activity in man. (0 citation(s)) 29060/163 Phase 1 A study to assess the pharmacokinetics and tolerance of single oral doses and repeat oral doses of paroxetine in healthy elderly subjects and a control population. (0 citation(s)) 29060/164 Phase 1 A study to assess the pharmacokinetics and tolerance of single and repeat oral doses of paroxetine in healthy elderly subjects and a young adult control group. (1 citation(s)) 29060/165 Phase 1 Pharmacokinetics of paroxetine in patients with hepatic dysfunction (0 citation(s)) 29060/166 Phase 1 Study to elucidate any interaction between four anticonvulsants and paroxetine (0 citation(s)) 29060/167 Phase 1 An investigation into the action of oral paroxetine on upper gastro-intestinal activity in man using the lactulose/breath hydrogen method (0 citation(s)) 29060/168 Phase 1 An open two-part crossover study in healthy male volunteers to examine the effects of co-administration of Aludrox on the pharmacokinetics of BRL 29060 (paroxetine) after single oral dose of 30 mg BRL 29060 (1 citation(s)) 29060/169 Phase 1 Pharmacokinetics of paroxetine before and after an eventual liver enzyme induction caused by multiple oral dosing of phenobarbitone to healthy male volunteers (1 citation(s)) 29060/170 Phase 1 A single-blind study to examine the pharmacokinetics and tolerance of paroxetine and propranolol and any interaction between them under steady state conditions (0 citation(s)) 29060/171 Phase 1 Pharmacokinetics and effects of tranylcypromine and paroxetine and any interaction between them in healthy male volunteers (0 citation(s)) 29060/172 Phase 1 A single-blind, two-part, placebo-controlled study to investigate the pharmacokinetics and effects of paroxetine (BRL 29060A) and procyclidine and any interaction between them in healthy male volunteers (0 citation(s)) 29060/173 Phase 1 An open two-part study to investigate the effects of paroxetine (BRL 29060) on the pharmacokinetics of digoxin and cardiovascular tolerance (0 citation(s)) 29060/174 Phase 1 An open study for the pharmacokinetics of orally administered paroxetine before and after oral administration of cimetidine to healthy male volunteers. (0 citation(s)) 29060/175 Phase 1 An open two-part crossover study to investigate bioavailability of BRL 29060 (Paroxetine) in healthy male volunteers after a single oral dose of 30mg BRL 29060 with a high fat and a low fat diet. (1 citation(s)) 29060/176 Phase 1 An investigation of the single-dose pharmacokinetics of BRL 29060 (30 mg pfb) in elderly healthy volunteers (0 citation(s)) 29060/177 Phase 1 A single-blind study to determine pharmacokinetics and tolerance of paroxetine and methyldopa and any interaction between them under steady state conditions of both compounds (0 citation(s)) 29060/178 Phase 1 A single dose pharmacokinetic study with paroxetine in subjects with hepatic impairment (1 citation(s)) 29060/179 Phase 1 Pharmacokinetics of paroxetine before and after multiple oral dosing of phenytoin to healthy male volunteers (0 citation(s)) 29060/180 Phase 1 An open two-part crossover study to investigate bioavailability of BRL 29060 (Paroxetine) in healthy male volunteers after a single oral dose of 30 mg with and without the concurrent administration of milk. (1 citation(s)) 29060/181 Phase 1 An open two-part crossover study to investigate the bioavailability of BRL 29060 (Paroxetine) in healthy male volunteers after a single oral dose of 60 mg BRL 29060 with and without activated charcoal. (1 citation(s)) 29060/182 Phase 1 A double-blind, placebo controlled two-part crossover study to investigate bioavailability of BRL 29060 (paroxetine) in healthy male volunteers after a single oral dose of 60 mg BRL 29060 in the fasting and non-fasting states. (0 citation(s)) 29060/183 Phase 1 Open single dose pharmacokinetic study with paroxetine in elderly volunteers (0 citation(s)) 29060/187 Phase 3 A Double-Blind Placebo Controlled Comparative Study of Paroxetine and Clomipramine in the Treatment of Panic Disorder. (2 citation(s)) 29060/189 Phase 4 A Double-Blind Randomized Study to Provide Safety Information on Switching Fluoxetine-Treated Patients to Paroxetine without an Intervening Washout Period (1 citation(s)) 29060/190 Phase 3 A Double-Blind, Comparative, Placebo-Controlled Trial of Paroxetine in the Prevention of Recurrent Depression (2 citation(s)) 29060/197 Phase 3 A Double-Blind Comparison of the Efficacy and Tolerability of Paroxetine and Imipiramine in the Treatment of Depression and Behavioural Disturbance Associated with Dementia (4 citation(s)) 29060/201 Phase 3 A Double-Blind, Placebo Controlled Study, to Assess the Efficacy of Paroxetine in the Prevention of Relapse Following Detoxification in Alcoholics (0 citation(s)) 29060/222 Phase 3 A Double-Blind, Placebo-Controlled, Continuation of Study 29060/120 to Assess the Long Term Safety and Efficacy of Paroxetine in the Treatment of Panic Disorder and its Role in the Prevention of Relapse/Recurrence (7 citation(s)) 29060/223 Phase 3 A Double-Blind, Multicentered, Flexible-Dose Study of Paroxetine, Alprazolam and Placebo in the Treatment of Panic Disorder (0 citation(s)) 29060/228 Phase 3 A Long-Term Extension of a Double-Blind, Placebo -Controlled Comparative Study of Paroxetine and Clomipramine in the Treatment of Panic Disorder (2 citation(s)) 29060/238 Phase 1 A study to determine the steady-state pharmacokinetics of paroxetine (20 mg o.d. p.o. for 18 days) in subjects with impaired renal function. (0 citation(s)) 29060/239 Phase 4 A Randomized, Comparative Study of Paroxetine in the Treatment of Depression as Used in a Clinical Practice Setting (3 citation(s)) 29060/239_1 Phase 3 A Randomized, Comparative Study of Paroxetine in the Treatment of Depression as Used in a Clinical Practice Setting (0 citation(s)) 29060/241 Phase 3 A Double-Blind Study to Compare the Maintenance of Efficacy and Relapse Rates in Patients with Obsessive Compulsive Disorder who Responded to Paroxetine, Clomipramine or Placebo in the Short Term Study 136. (0 citation(s)) 29060/243 Phase 1 An open study to investigate the effects of repeated dosing of paroxetine (20 mg OD for 38 days) on the pharmacokinetics and metabolism of a single dose of desipramine (100 mg) in healthy volunteer subjects (0 citation(s)) 29060/245 Phase 3 A Double-Blind, Multicentre Study in Primary Care Comparing Paroxetine and Clomipramine in Patients with Depression with Associated Anxiety (2 citation(s)) 29060/251 Phase 3 A Double-Blind, Randomized Trial of Paroxetine Versus Placebo In Patients With Depression Accompanied by Anxiety (0 citation(s)) 29060/252 Phase 3 A Multicentre Open Study to Investigate the Safety and Efficacy of Paroxetine in the Treatment of Depressed Patients (0 citation(s)) 29060/253 Phase 3 An Open Pharmacokinetic and Pharmacodynamic Study of Paroxetine (20 – 50mg daily) in the Treatment of Major Depressive Disorder (DSM III) (1 citation(s)) 29060/256 Phase 3 A Study of the Efficacy and Safety of Paroxetine in Subjects with Depression (2 citation(s)) 29060/257 Phase 3 An Open Multicentre Study to Assess the Safety and Efficacy of Paroxetine in Patients with Depression (0 citation(s)) 29060/258 Phase 2 An Early Clinical Phase II Evaluation of Paroxetine, a New Product and 5-HT Uptake Inhibitor in Patients with Depressive Illness (1 citation(s)) 29060/259 Phase 2 Paroxetine, a Selective Serotonin Uptake Inhibitor in the Treatment of Depressive Illness – a Clinical Phase II Study (0 citation(s)) 29060/260 Phase 3 Paroxetine in the treatment of depression – a randomised comparison with amitriptyline. (1 citation(s)) 29060/261 Phase 3 A Double-Blind, Comparative Study of Paroxetine and Clomipramine to Assess Efficacy and to Evaluate the Correlation Between Plasma Concentration and Effect (1 citation(s)) 29060/268 Phase 3 A study to assess the efficacy and safety of paroxetine in patients with depression (0 citation(s)) 29060/270 Phase 1 Comparison of the effects of single doses of paroxetine, amitriptyline and placebo on systolic time intervals in volunteers (2 citation(s)) 29060/272 Phase 3 A Comparison of the Efficacy and Tolerance of Paroxetine and Amitriptyline in the Treatment of Depression. A Double-Blind, Parallel Study (0 citation(s)) 29060/276 Phase 2 A double-blind study to investigate the efficacy, safety and tolerability of Paroxetine in the treatment of depression in comparison with placebo (1 citation(s)) 29060/277 Phase 1 The effect of paroxetine taken in the evening, on sleep in human non-depressed, poor sleepers (1 citation(s)) 29060/278 Phase 1 The effect of paroxetine taken in the morning on sleep in human non-depressed, poor sleepers (0 citation(s)) 29060/281 Phase 3 A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline in the treatment of depressed patients in General Practice (0 citation(s)) 29060/282 Phase 3 A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo using a novel “shifted crossover” design (1 citation(s)) 29060/283/014B Phase 3 The Short Term Phase of an Open, Long-Term, Safety and Tolerability Study of Paroxetine in Patients Suffering from Depression (0 citation(s)) 29060/284 Phase 1 A comparison of the effect of paroxetine and amitriptyline in single doses on psychomotor performance (0 citation(s)) 29060/285 Phase 1 To assess the effect of repeated dosing with paroxetine, amitriptyline and placebo on psychomotor skills and cardiac function in volunteers (2 citation(s)) 29060/286 Phase 3 An investigation of the pharmacokinetics, efficacy, and tolerance of paroxetine in geriatric patients with depression (0 citation(s)) 29060/287 Phase 3 A Report on the Short-Term Phase of an Open Long-Term Study to Investigate the Safety of Paroxetine in Geriatric Patients (0 citation(s)) 29060/289 Phase 3 A Study to Assess the Efficacy and Tolerance of Paroxetine in Patients with Depression by Double-Blind Comparison with Clomipramine (0 citation(s)) 29060/290 Phase 3 A prospective, randomized, double-blind, multicentre study of the efficacy and tolerance of paroxetine versus clomipramine in the treatment of endogenous depression in the elderly (2 citation(s)) 29060/291 Phase 3 A Multi-Centre Double-Blind Study to Investigate the Safety and Efficacy of Paroxetine in Comparison with Clomipramine in the Treatment of Reactive Depression in Elderly Patients. (1 citation(s)) 29060/292 Phase 3 A multi-centre study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline (3 citation(s)) 29060/294 Phase 1 A study to investigate the effects of food on the bioavailability of a single 20 mg dose of ‘Paxil’ (paroxetine) in healthy volunteers (0 citation(s)) 29060/298 Phase 3 A double-blind study comparing the efficacy and tolerability of paroxetine and placebo in hospital out-patients with depressive symptoms associated with chronic back pain. (1 citation(s)) 29060/299 Phase 3 A Double-Blind Study Comparing The Efficacy and Tolerability of Paroxetine and Amitriptyline In Patients With Severe Depression. (0 citation(s)) 29060/303 Phase 1 A double blind, placebo controlled study to determine the effects of subchronic paroxetine treatment on nocturnal hormonal secretion and sleep in healthy male volunteers (4 citation(s)) 29060/308 Phase 2 Early clinical evaluation of a new antidepressant: A double-blind parallel study comparing paroxetine 30mg daily with amitriptyline 150mg daily (0 citation(s)) 29060/309 Phase 2 Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 100mg Daily (0 citation(s)) 29060/310 Phase 2 Early Clinical Evaluation of a New Antidepressant: Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily (1 citation(s)) 29060/311 Phase 2 Early clinical evaluation of a new antidepressant: An open pilot study of paroxetine 40mg daily (0 citation(s)) 29060/312 Phase 2 A Phase II Pharmacokinetic Double Blind Study Comparing Paroxetine with Amitriptyline in Depressed Patients (0 citation(s)) 29060/313 Phase 2 A study to assess the efficacy and pharmacokinetics of paroxetine in depressed geriatric patients (0 citation(s)) 29060/314 Phase 2 Double Blind Parallel Study Comparing Paroxetine, 30mg Daily, and Amitriptyline, 150mg Daily, in Depressed Patients (1 citation(s)) 29060/315 Phase 2 Early clinical evaluation of a new antidepressant: An open pilot study of paroxetine 40mg daily (0 citation(s)) 29060/316 Phase 2 Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily (1 citation(s)) 29060/317 Phase 2 An early clinical evaluation of a new antidepressant: An open study of paroxetine 40mg o.d. (0 citation(s)) 29060/318 Phase 2 Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily (1 citation(s)) 29060/319 Phase 2 Early clinical evaluation of a new antidepressant: A double-blind parallel study comparing paroxetine 30mg daily, with amitriptyline 150mg daily. (1 citation(s)) 29060/320 Phase 1 An open labelled study to investigate the safety and tolerability of paroxetine when single oral dosing of 40 mg of paroxetine in healthy volunteers (0 citation(s)) 29060/322 Phase 1 Phase I clinical investigation of paroxetine. The pharmacokinetics, safety and tolerance of single and repeat oral administration of paroxetine in healthy volunteers (0 citation(s)) 29060/326 Phase 3 A double-blind, randomised multi centre study to assess the safety and tolerability of paroxetine and amitriptyline in depressed subjects stabilised on lithium treatment (2 citation(s)) 29060/327 Phase 2 A double-blind, placebo-controlled, parallel group study of paroxetine in the treatment of dysthymia. (0 citation(s)) 29060/329 Phase 3 A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression - Acute PhasePhase: III Indication: Major DepressionPlease refer to the following URL to view the … (1 citation(s)) 29060/329_1 Phase 3 A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression Continuation Phase.Phase: IIIIndication: Major DepressionPlease refer to the following URL to view the entire clinical report for this study:http://www.gsk.com/media ... (0 citation(s)) 29060/331 Phase 4 Paroxetine in Depressed Patients with Ischemic Heart Disease- A Randomized Safety Study (7 citation(s)) 29060/332 Phase 4 A Double-Blind, Multicentre Study to Assess the Efficacy and Tolerability of Paroxetine and Amitriptyline in Patients With a Mild, Moderate, or Severe Depressive Episode Associated With Rheumatoid Arthritis (3 citation(s)) 29060/348 Phase 1 Bioequivalence study of paroxetine hydrochloride formulations: bioequivalence study between two paroxetine hydrochloride formulations (10 mg tablet and 20 mg tablet) in healthy adult volunteers (0 citation(s)) 29060/352 Phase 4 A Double-Blind, Placebo-Controlled, Comparison of Imipramine and Paroxetine in the Treatment of Bipolar Depression (1 citation(s)) 29060/353 Phase 3 A Ten-Week, Single-Blind, Multicentre Study Evaluating the Efficacy and Tolerability of Paroxetine vs. Desipramine in the Treatment of Outpatients with Major Depression According to DSM-III-R (0 citation(s)) 29060/356 Phase 3 A double-blind, multicentre study to compare paroxetine and fluoxetine in the treatment of patients with major depressive disorder with regard to antidepressant efficacy, effects on associated anxiety and tolerability. (0 citation(s)) 29060/356_1 Phase 3 Extension phase for a double-blind, multicentre study to compare paroxetine and fluoxetine in the treatment of patients with major depressive disorder with regard to antidepressant efficacy, effects on associated anxiety and tolerability. (0 citation(s)) 29060/358 Phase 4 Comparative study of paroxetine and mianserin in depression of the elderly: efficacy, tolerance, serotonin dependence. (1 citation(s)) 29060/360 Phase 1 A single dose, crossover study to determine the comparative bioavailability of an oral liquid preparation of paroxetine (30 mg pfb) and a 30 mg pfb paroxetine tablet (0 citation(s)) 29060/368 Phase 4 Belgian Paroxetine Experience: An open-label study evaluating the efficacy and safety of paroxetine in depressed patients treated by Belgian psychiatrists and general practitioners (1 citation(s)) 29060/374 Phase 1 A repeat-dose steady-state crossover evaluation of the bioequivalence of a 20 mg “wet granulation” standard Paxil™ tablet with a liquid formulation of paroxetine (20 mg p.f.b) (0 citation(s)) 29060/377 Phase 3 A Double-blind, Multicentre Placebo-Controlled Study of Paroxetine in Adolescents with Unipolar Major Depression. (1 citation(s)) 29060/382 Phase 4 A Randomized, Double-Blind, Comparison of Paroxetine and Placebo in the Treatment of Generalized Social Phobia (5 citation(s)) 29060/391 Phase 1 A double-blind study of the effects of paroxetine, fluoxetine and placebo on driving ability in healthy volunteers (1 citation(s)) 29060/395 Phase 4 Double-blind, randomised study to compare the effects of paroxetine and amitriptyline on driving ability and psychomotor performance in patients with mild to moderate depression treated for at least 4 weeks (0 citation(s)) 29060/397 Phase 4 A double-blind multicentre study to assess the tolerability and efficacy of paroxetine compared with amitriptyline in the treatment of depressed patients in general practice (2 citation(s)) 29060/398 Phase 1 Pharmacokinetics of paroxetine 10 mg, 20 mg and 40 mg in single oral administration in healthy volunteers (0 citation(s)) 29060/400 Phase 3 A Double-Blind, Placebo Controlled Study to Investigate the Efficacy, Safety and Tolerability of Paroxetine in Patients with Premenstrual Dysphoric Disorder. (0 citation(s)) 29060/402 Phase 4 A double-blind, multicentre, parallel group study of paroxetine and amitriptyline in the treatment of patients with depression associated with breast cancer (4 citation(s)) 29060/403 Phase 3 Antidepressant efficacy and safety of paroxetine; a double blind amitriptyline controlled multicenter comparison study in depressive patients. (0 citation(s)) 29060/406 Phase 4 A Double-Blind, Long-Term Extension Study for Patients Previously Participating in Protocol 29060/131 (0 citation(s)) 29060/409 Phase 4 A comparative, controlled double blind, double dummy study about the efficacy and safety of paroxetine vs imipramine in ambulatory patients with major depression (0 citation(s)) 29060/418 Phase 1 A single-dose 3-part crossover study to determine the comparative bioavailability of two oral liquid preparations of paroxetine (30 mg pfb) and a 30 mg tablet of paroxetine (0 citation(s)) 29060/419 Phase 1 A repeat-dose steady-state crossover evaluation of the bioequivalence of a 20 mg direct compression tablet of paroxetine with a 20 mg standard “Paxil” tablet (0 citation(s)) 29060/421 Phase 3 Paroxetine and Fluoxetine effects on mood and cognitive function in depressed nondemented elderly patients. Extensive searching has revealed that no clinical report is available for this study. The clinical trial results were reported via publications; see citation below. (1 citation(s)) 29060/427 Phase 2 A Multicentre, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Paroxetine (5mg OD Vs 10mg OD Vs 20mg OD) in Patients with Premenstrual Dysphoric Disorder (PMDD). (0 citation(s)) 29060/433 Phase 3 Treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor (0 citation(s)) 29060/436 Phase 4 Safety Evaluation of Paroxetine in Elderly Depressed Patients (0 citation(s)) 29060/437 Phase 3 A Double-blind, Placebo-controlled Study to Investigate the Effect of Pindolol on the Onset of Anti-depressant Activity of Paroxetine in the Treatment of Depression. (1 citation(s)) 29060/440 Phase 1 A single dose 4-part crossover study to determine the comparative bioavailability of an oral liquid formulation of paroxetine (20 mg pfb) and a standard 20 mg pfb Paxil tablet administered immediately before and after breakfast (0 citation(s)) 29060/442 Phase 4 A multicentre, randomised, double-blind study to compare paroxetine versus placebo in the treatment of double depression. (0 citation(s)) 29060/448 Phase 3 A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression (5 citation(s)) 29060/449 Phase 3 A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression (5 citation(s)) 29060/451 Phase 1 An open 5 part crossover study to examine the bioavailability characteristics of two controlled-release and two delayed-release oral formulations of paroxetine (20 mg), in comparison with a standard 20 mg tablet, in healthy volunteers (0 citation(s)) 29060/452 Phase 1 A double-blind, placebo-controlled, parallel group study to investigate the incidence of nausea following 3 days treatment with modified release formulations of paroxetine compared with the standard immediate release paroxetine tablet at a dose level of 30 mg in healthy volunteers (0 citation(s)) 29060/453 Phase 3 A 38-Week, Two Phase, Multi-center Study to Investigate the Safety and Effectiveness of paroxetine (10-60mg/day in the Treatment of Children and Adolescent Outpatients with Obsessive Compulsive Disorder (OCD) (1 citation(s)) 29060/454 Phase 3 A Randomized, Double-Blind, Fixed Dose Comparison of 20, 40, and 60mg Daily of Paroxetine and Placebo in the Treatment of Generalized Social Phobia. (1 citation(s)) 29060/464 Phase 1 Bioequivalence study of paroxetine hydrochloride formulations: bioequivalence study between two paroxetine hydrochloride 20 mg tablets of different formulas (new and old formula tablets) in healthy adult volunteers (0 citation(s)) 29060/470 Phase 3 An Extension Trial Comparing Paroxetine and Placebo in the Long Term Treatment of Generalized Social Phobia (2 citation(s)) 29060/472 Phase 1 A randomised, open, four-period crossover study to compare the pharmacokinetic profile of paroxetine after single doses of each enteric coated Geomatrix controlled-release tablet strength (12.5, 25, 37.5 and 50 mg) (0 citation(s)) 29060/473 Phase 1 A single dose, two-period crossover study to compare the bioavailability of paroxetine from the enteric-coated Geomatrix controlled-release paroxetine tablet (50 mg) when administered in the fasted state and after a standard FDA high-fat breakfast (0 citation(s)) 29060/474 Phase 1 A steady-state, two-period crossover study to compare the pharmacokinetic profile of paroxetine after repeated daily dosing of the controlled release paroxetine tablet (50 mg) with that of standard immediate release paroxetine (Paxil, 40 mg) (0 citation(s)) 29060/475 Phase 1 Pharmacokinetic study of paroxetine hydrochloridePharmacokinetics after single oral administration of paroxetine hydrochloride 20 mg to healthy elderly volunteers (0 citation(s)) 29060/480 Phase 1 A single-dose, two-period crossover study to demonstrate bioequivalence between the controlled-release paroxetine tablet (50 mg) manufactured at Cidra and two 25 mg controlled-release tablets manufactured at Crawley (0 citation(s)) 29060/485 Phase 1 An open 3 part crossover study to examine the bioavailability characteristics of slow release oral formulations of paroxetine (30 mg dose), in comparison with a standard, immediate release 30 mg tablet, in healthy volunteers (0 citation(s)) 29060/486 Phase 1 The effects of paroxetine on the pharmacodynamics and pharmacokinetics of terfenadine in healthy adult males (1 citation(s)) 29060/487 Phase 3 A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression in Elderly Patients (3 citation(s)) 29060/494 Phase 3 A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Modified-Release Paroxetine in the Treatment of Panic Disorder (2 citation(s)) 29060/495 Phase 3 A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder (2 citation(s)) 29060/497 Phase 3 A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder (2 citation(s)) 29060/502 Phase 3 A Randomised, Double-blind Study of Paroxetine and Placebo in the Treatment of Social Phobia (2 citation(s)) 29060/505 Phase 1 An open 4 part crossover study to examine the bioavailability characteristics of the paroxetine enteric-coated geomatrix tablet (25 mg) and two novel formulations of the paroxetine geomatrix tablet (20 mg), in comparison with a standard immediate-release paroxetine (20 mg) tablet in healthy volu ... (0 citation(s)) 29060/509 Phase 3 An open, non-comparative multi-centre study to assess the efficacy and tolerability of paroxetine 20mg daily in the treatment of depression and depression associated with anxiety (1 citation(s)) 29060/512 Phase 3 A multi-centre, double-blind placebo-controlled study to investigate the effect of pindolol on the onset of antidepressant activity of paroxetine in the treatment of depression. (2 citation(s)) 29060/516 Phase 4 A post-marketing surveillance to monitor the safety of Seroxat (paroxetine hydrochloride) administered in Korean subjects according to the prescribing information. (0 citation(s)) 29060/517 Phase 1 An open 3 way crossover study to examine the effect of paroxetine on the pharmacokinetics of pindolol, in healthy volunteers. (1 citation(s)) 29060/518 Phase 3 A multi-centre, double-blind, double dummy, randomised controlled study to investigate the speed of onset, safety, efficacy and tolerability of paroxetine in combination with pindolol compared with dothiepin in the treatment of depression. (0 citation(s)) 29060/523 Phase 4 Open prospective study to evaluate the efficacy and safety of paroxetine in the treatment of Panic Disorder and Obsessive-Compulsive Disorder (0 citation(s)) 29060/524 Phase 4 An open multicentre prospective study to compare antidepressive activity of paroxetine in monotherapy and paroxetine combined with pindolol in the treatment of depression (0 citation(s)) 29060/525 Phase 3 A double blind, multicenter randomized drug-controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of panic disorder. (0 citation(s)) 29060/526 Phase 3 A double blind, multicenter, randomized, drug-controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of obsessive compulsive disorder. (0 citation(s)) 29060/533 Phase 1 A study to demonstrate the bioequivalence between the paroxetine capsule and the Paxil tablet formulations at the highest and lowest dosage strengths. (0 citation(s)) 29060/536 Phase 4 A Randomized, Open Trial to Compare Patient Medication Compliance, Efficacy and Quality of Life in Patients Receiving Paroxetine, (20 mg OD) Dispensed in Bottles Compared with Paroxetine, (20 mg OD) Dispensed in Blister Packaging (0 citation(s)) 29060/539 Phase 1 A single dose two-period crossover study to demonstrate bioequivalence between the controlled release paroxetine tablet (25 mg) manufactured at Cidra and Crawley (0 citation(s)) 29060/560 Phase 1 A single dose two-period cross-over study to compare the bioavailability of a paroxetine/pindolol combination tablet (containing 20 mg paroxetine and 7.5 mg controlled release pindolol) when administered in the fed and fasted state (0 citation(s)) 29060/563 Phase 1 A single dose, five-period crossover study to assess the bioavailability of paroxetine from the controlled release paroxetine tablet (50 mg) when administered in four different fed states relative to administration in the fasted state. (0 citation(s)) 29060/564 Phase 1 A steady state study to assess the pharmacokinetic profile of paroxetine after repeated daily dosing of the controlled release paroxetine tablet (25 mg) when given fasted and when given immediately after a standard FDA high-fat breakfast (0 citation(s)) 29060/569 Phase 1 A single dose, four period crossover replicate study to demonstrate bioequivalence between controlled release paroxetine tablets (2 x 12.5mg) manufactured at Cidra and Crawley. (0 citation(s)) 29060/572 Phase 1 A single dose, two-period crossover study to compare the bioavailability of paroxetine from the dispersible tablet (20 mg, final formulation) when administered in the fasted state and after a standard FDA high-fat breakfast (0 citation(s)) 29060/578 Phase 1 A single dose, group sequential, four period crossover study to demonstrate bioequivalence between 37.5 mg and 12.5 mg + 25 mg controlled release paroxetine tablets manufactured at Cidra (0 citation(s)) 29060/579 Phase 1 A single dose, four-period crossover study to demonstrate bioequivalence between 25mg controlled-release paroxetine tablets manufactured at Cidra and Crawley. (0 citation(s)) 29060/595 Phase 3 A Study of the Maintained Efficacy and Safety of Paroxetine versus Placebo in the Long-Term Treatment of Social Phobia (1 citation(s)) 29060/621 Phase 4 A randomized, double-blind, placebo-controlled trial of intermittent treatment with paroxetine 10mg/day and 20mg/day versus placebo in Canadian women with Premenstrual Dysphoric Disorder (0 citation(s)) 29060/622 Phase 4 Open study to evaluate the efficacy and safety of paroxetine in the treatment of minor depression. (0 citation(s)) 29060/625 Phase 3 An 8-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering From Depression Following Stroke (0 citation(s)) 29060/627 Phase 3 A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Posttraumatic Stress Disorder (PTSD) (1 citation(s)) 29060/637 Phase 3 A double-blind, placebo controlled study to evaluate the efficacy and tolerability of paroxetine in patients with Generalised Anxiety Disorder (GAD) (1 citation(s)) 29060/641 Phase 3 A Randomized, Double-Blind, Placebo Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of 20 and 40mg/day Paroxetine in Patients with Generalized Anxiety Disorder (1 citation(s)) 29060/642 Phase 3 A Randomized, Double-Blind, Placebo Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine in Patients with Generalized Anxiety Disorder (3 citation(s)) 29060/645 Phase 1 A single-dose, group sequential, four period crossover study to demonstrate bioequivalence between 50 mg and two 25 mg controlled release paroxetine tablets manufactured at Cidra (0 citation(s)) 29060/646 Phase 3 A Study of the Maintained Efficacy and Safety of Paroxetine in Patients with Generalized Anxiety Disorder (GAD) (3 citation(s)) 29060/648 Phase 3 A 12 Week, Double-blind, Placebo-controlled, parallel group study to assess the efficacy and tolerability of Paroxetine in Patients suffering from Posttraumatic Stress Disorder (PTSD) (1 citation(s)) 29060/650 Phase 3 A Study of the Maintained Efficacy and Safety of Paroxetine Versus Placebo in the Long-Term Treatment of Posttraumatic Stress Disorder (0 citation(s)) 29060/651 Phase 3 A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). (5 citation(s)) 29060/653 Phase 1 A single dose four-period crossover study to investigate the relative bioavailability of the new paroxetine dispersible tablet (20 mg) compared with a standard paroxetine 20 mg tablet (0 citation(s)) 29060/658 Phase 3 A Placebo-Controlled Study to Investigate the Efficacy of Intermittent and Continuous Treatment With Paroxetine in Patients With Premenstrual Dysphoric Disorder (PMDD) (1 citation(s)) 29060/661 Phase 2/Phase 3 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) A Double-blind, Placebo-controlled Study (0 citation(s)) 29060/663 Phase 1 A single dose two-period cross-over study to demonstrate bioequivalence between a new paroxetine tablet (40 mg) and the standard Paxil tablet (40 mg) (0 citation(s)) 29060/664 Phase 1 A single dose randomised three-period cross-over study to evaluate the effect of food on the bioavailability of a new 40 mg paroxetine tablet when administered in the fed and fasted state relative to the bioavailability of the standard 40 mg Paxil™ tablet administered in the fed state. (0 citation(s)) 29060/665 Phase 1 A Phase I Pharmacokinetic and Pharmacodynamic Study on the Potential Drug-Drug Interactions between Paroxetine and Alprazolam (2 citation(s)) 29060/676 Phase 3 A 16 Week Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Paroxetine in the Treatment of Children and Adolescents with Social Anxiety Disorder/Social Phobia. (1 citation(s)) 29060/677 Phase 3 A Double-Blind, Placebo-Controlled, Three-Arm Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder (5 citation(s)) 29060/681 Phase 4 Open study to evaluate the efficacy and the safety of paroxetine in the treatment of depression associated with a physical disorders (0 citation(s)) 29060/688 Phase 3 A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder (3 citation(s)) 29060/689 Phase 3 A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder (4 citation(s)) 29060/701 Phase 3 A Randomized, Multi-center, 8-week, Double-blind, Placebo-Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) (1 citation(s)) 29060/704 Phase 3 A Randomized, Multi-center, 10-week, Double-blind, Placebo-Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with Obsessive Compulsive Disorder (1 citation(s)) 29060/711 Phase 3 A 3-Month, Double-blind, Placebo-controlled, Fixed-dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg/day) Continuous Treatment for PMDD Patients Completing Studies 29060/677, 688 or 689 (2 citation(s)) 29060/715 Phase 3 A Multi-center Study to Assess the Pharmacokinetics of Paroxetine Following Repeat-Dose Administration in Children and Adolescents with Obsessive Compulsive Disorder (OCD) and/or Depression (1 citation(s)) 29060/716 Phase 3 A Multi-center, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive Compulsive Disorder (OCD) (0 citation(s)) 29060/717 Phase 3 A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder (0 citation(s)) 29060/730 Phase 3 Clinical comparison of paroxetine and placebo on the symptoms emerging during the taper phase of a chronic benzodiazepine treatment, in patients suffering from a variety of anxiety disorders (0 citation(s)) 29060/785 Phase 4 A double-blind, placebo-controlled, fixed-dosage study comparing the efficacy and tolerability of paroxetine CR and citalopram to placebo in the treatment of Major Depressive Disorder with anxiety (1 citation(s)) 29060/790 Phase 3 A Double-blind, Placebo-controlled, Flexible-dose Study of Paroxetine CR in the Treatment of Patients with Social Anxiety Disorder (4 citation(s)) 29060/791 Phase 3 A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine CR in Patients with Generalized Anxiety Disorder (GAD) (0 citation(s)) 29060/799 phase 3 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A 52-Week, Non-Comparative, Uncontrolled Study for the Clinical Use Experience - <Open-Label Study> (1 citation(s)) 29060/810 Phase 4 A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Efficacy and Safety of Paroxetine Controlled Release (12.5 and 25 mg/day) Versus Placebo in Patients with Major Depressive Disorder (2 citation(s)) 29060/863 Phase 4 A Post-Marketing Clinical Study of PAXIL Tablet in Patients with Depression or Depressive Episodes (0 citation(s)) 29060/874 phase 3 A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of Paroxetine CR in Elderly Outpatients Diagnosed with Major Depressive Disorder (1 citation(s)) 29060/877 Phase 1 An open labeled, single sequence study to investigate the safety and pharmacokinetics of oral pimozide when co-administered with repeat dosing oral paroxetine 60 mg od in healthy volunteers. (0 citation(s)) 999910/126 Phase 1 A placebo-controlled, randomised, double-blinded, parallel group study in healthy volunteers to assess the effects of paroxetine on ejaculation and accompanying neurohumoral parameters. (0 citation(s)) Article-31 N/A Article 31 referral analyses of GSK’s clinical trial data to evaluate the risk of suicide, suicidal thoughts and behaviours, and self-harm, with particular attention to potential risk factors including age and gender (0 citation(s)) BRL29060A/856 phase 2 Clinical Evaluation of BRL29060 A in Generalized Anxiety Disorder (0 citation(s)) EPI40404 Phase 4 EPIDEMIOLOGY STUDY: Paroxetine in the First Trimester and the Prevalence of Congenital Malformations (Follow-up to Epidemiology Study: Final Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformations) (0 citation(s)) HM2006/00198/00 Phase 1 A randomised, double-blind, parallel-group, placebo controlled study to investigate the anxiolytic effects of repeat dosing of 20mg and 40mg paroxetine. (0 citation(s)) MY-060/BRL-029060/1. Phase 3 A multicentre, double-blind, randomised dose titration study comparing the pharmacodynamics and pharmacokinetics of paroxetine 20mg increasing to 30mg daily and amitriptyline 100mg increasing to 150mg daily in geriatric patients (age &gt;65 years) with major depression. (2 citation(s)) NKG10006 Phase 1 A Randomized, Double-Blind, Placebo-Controlled, Three Armed fMRI study Comparing Emotion-Induced Brain Activation Patterns Before and After 8 Weeks of Treatment With Placebo, Active Comparator (PAXIL, 20 mg), and a GSK New Chemical Entity (NCE) (0 citation(s)) NKP102280 phase 2 See Detailed Description (0 citation(s)) PAR MDSA/29060/III/86/1182 Phase 3 A Study to Assess the Tolerance of Paroxetine in Short and Long Term Therapy and to Assess the Efficacy and Tolerance in a Subset of Patients in whom Previous Antidepressant Therapy had Failed. An Open Study (0 citation(s)) PAR03_001 Phase 3 A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients (3 citation(s)) PCR103124 phase 3 A Multicentre, Double-blind, Active Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression (0 citation(s)) PCR104074 Phase 1 A randomized, open, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single dosing of each enteric-coated Geomatrix control release tablet strength (12.5, 25, 37.5mg) in healthy Chinese subjects (0 citation(s)) PCR104075 Phase 1 A steady-state study to assess the pharmacokinetic profile of paroxetine after 14 day repeated daily dosing of the controlled release paroxetine tablet (25 mg) in healthy Chinese subjects (0 citation(s)) PCR111656 phase 1 An open-label, randomized, single dose, two-period crossover study to demonstrate bioequivalence between the controlled release paroxetine tablet (37.5 mg) manufactured at Cidra and Mississauga (0 citation(s)) PIR104776 phase 3 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- <Phase III Study> (0 citation(s)) PIR104777 phase 3 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study- <Phase III Study> (0 citation(s)) PIR109164 phase 2 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A Placebo-controlled, Single-Blind Comparative Study - (1 citation(s)) SB29060.833 Phase 4 An open label study assessing Paxil CR (paroxetine CR) in patients with major depressive disorder who discontinued treatment with selective serotonin reuptake inhibitors or a selective serotonin/norepinephrine reuptake inhibitor due to intolerability (0 citation(s)) SX12003 Phase 4 Treatment of depressed and/or anxiety subjects with paroxetine in the primary care. (0 citation(s)) Taiwan-PAR Phase 4 Paroxetine in the Treatment of Chinese Patients with Depressive Episodes – A Double-blind randomized Comparison with Imipramine (0 citation(s)) TMT106386 Phase 1 A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects with Social Anxiety Disorder (0 citation(s))
